Boston Children's Hospital is monitoring the developing situation with lead contamination in some Boston Public Schools. Please contact your primary care physician if you have any concerns about your child.
Boston Children’s Hospital está monitoreando la situación de la contaminación por plomo en algunas escuelas públicas de Boston. Por favor, póngase en contacto con su médico primario si usted tiene alguna preocupación acerca de su hijo.
Ranked #1 Children's Hospital by U.S. News & World Report
MyPatients provides referring primary care providers with secure access to their patients’ information.
Boston Children's has launched the world's 1st program dedicated to offering hand transplants to children who qualify.
Innovation insider is a semi-monthly e-newsletter analyzes innovations at Boston Children’s, other academic medical centers and from industry.
Read the latest blog by a Boston Children's doctor, clinician or staff member.
Support the hospital with a donation that helps kids get the care they need.
Malignant rhabdoid tumor is a rare childhood tumor that commonly starts in the kidneys but also can occur in other soft tissues or in the brain, where it is referred to as atypical teratoid/rhabdoid tumor.
Malignant rhabdoid tumor occurs most commonly in infants and toddlers; the average age of diagnosis is 15 months old. There are about 20 to 25 new cases of malignant rhabdoid tumor diagnosed each year in the United States. Cells from a malignant rhabdoid tumor can spread (metastasize) to other areas of the body.
The treatment of malignant rhabdoid tumor involves a combination of therapies including surgery, radiation and chemotherapy. However, because this tumor is rare and aggressive, there is no defined standard of care, and treatment options may be tailored to your child's situation. Your child's doctor and other members of your care team will discuss the options with you in depth. Prompt medical attention and aggressive therapy are important for the best prognosis.
Dana-Farber/Boston Children’s Cancer and Blood Disorders Center is a world-leading center in the research and treatment of rhabdoid tumors. Our vibrant program of basic and translational research into rhabdoid tumors is uncovering new opportunities to improve the care of children with malignant rhabdoid tumor. Our multidisciplinary treatment approach through our Kidney Tumor Program ensures in-depth discussion of each child and personalized treatment plans for every patient.
Find more in-depth information on malignant rhabdoid tumor on the Dana-Farber/Boston Children’s website, including answers to:
The future of pediatrics will be forged by thinking differently, breaking paradigms and joining together in a shared vision of tackling the toughest challenges before us.”